# DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

> clinical trial · VERIFIED · 2026-08-17

Status: RECRUITING · Sponsor: Boehringer Ingelheim · Condition: Small Cell Lung Cancer (SCLC)

- Company: Boehringer Ingelheim
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07472517

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.